Organisation · Unternehmen
BioNTech SE
biontech-se-eutr-53796642
Aussagen (8)
eu transparency category
Companies & groups
dokumentiert
[Q-18489]
eu transparency goals
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
dokumentiert
[Q-18489]
eu transparency id
516273537966-42
dokumentiert
[Q-7535]
headquarters city
Mainz
dokumentiert
[Q-18489]
headquarters country
DE
dokumentiert
[Q-18489]
interest class
business_company
dokumentiert
[Q-29773]
legal form
Societas Europaea
dokumentiert
[Q-18489]
legal form class
kapitalgesellschaft
berichtet
[Q-29773]